Please use this identifier to cite or link to this item:
https://doi.org/10.3389/fmicb.2015.01322
DC Field | Value | |
---|---|---|
dc.title | Optimizing outcomes in immunocompromised hosts: Understanding the role of immunotherapy in invasive fungal diseases | |
dc.contributor.author | Ravikumar, S | |
dc.contributor.author | Win, M.S | |
dc.contributor.author | Chai, L.Y.A | |
dc.date.accessioned | 2020-09-03T10:35:33Z | |
dc.date.available | 2020-09-03T10:35:33Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Ravikumar, S, Win, M.S, Chai, L.Y.A (2015). Optimizing outcomes in immunocompromised hosts: Understanding the role of immunotherapy in invasive fungal diseases. Frontiers in Microbiology 6 (NOV) : 1322. ScholarBank@NUS Repository. https://doi.org/10.3389/fmicb.2015.01322 | |
dc.identifier.issn | 1664302X | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/174131 | |
dc.description.abstract | A major global concern is the emergence and spread of systemic life-threatening fungal infections in critically ill patients. The increase in invasive fungal infections, caused most commonly by Candida and Aspergillus species, occurs in patients with impaired defenses due to a number of reasons such as underlying disease, the use of chemotherapeutic and immunosuppressive agents, broad-spectrum antibiotics, prosthetic devices and grafts, burns, neutropenia and HIV infection. The high morbidity and mortality associated with these infections is compounded by the limited therapeutic options and the emergence of drug resistant fungi. Hence, creative approaches to bridge the significant gap in antifungal drug development needs to be explored. Here, we review the potential anti-fungal targets for patient-centered therapies and immune-enhancing strategies for the prevention and treatment of invasive fungal diseases. © 2015 Ravikumar, Win and Chai. | |
dc.source | Unpaywall 20200831 | |
dc.subject | antigen recognition | |
dc.subject | cell therapy | |
dc.subject | cell transfer | |
dc.subject | clinical trial (topic) | |
dc.subject | cross reaction | |
dc.subject | fungal virulence | |
dc.subject | granulocyte transfusion | |
dc.subject | human | |
dc.subject | immune response | |
dc.subject | immunocompromised patient | |
dc.subject | immunological tolerance | |
dc.subject | immunoregulation | |
dc.subject | immunotherapy | |
dc.subject | mycosis | |
dc.subject | natural killer cell | |
dc.subject | nonhuman | |
dc.subject | protein expression | |
dc.subject | Review | |
dc.subject | risk factor | |
dc.subject | signal transduction | |
dc.subject | vaccination | |
dc.type | Review | |
dc.contributor.department | CANCER SCIENCE INSTITUTE OF SINGAPORE | |
dc.contributor.department | MEDICINE | |
dc.description.doi | 10.3389/fmicb.2015.01322 | |
dc.description.sourcetitle | Frontiers in Microbiology | |
dc.description.volume | 6 | |
dc.description.issue | NOV | |
dc.description.page | 1322 | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_3389_fmicb_2015_01322.pdf | 529.3 kB | Adobe PDF | OPEN | None | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.